

# Christopher J O'donnell

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7662151/publications.pdf>

Version: 2024-02-01

32  
papers

1,590  
citations

304743

22  
h-index

414414

32  
g-index

33  
all docs

33  
docs citations

33  
times ranked

1955  
citing authors

#	ARTICLE	IF	CITATIONS
1	Molecular Basis of Valine-Citrulline-PABC Linker Instability in Site-Specific ADCs and Its Mitigation by Linker Design. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 958-970.	4.1	141
2	Kinetically guided radical-based synthesis of C(sp <sup>3</sup> )-C(sp <sup>3</sup> ) linkages on DNA. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E6404-E6410.	7.1	124
3	Discovery of Cytotoxic Dolastatin 10 Analogues with N-Terminal Modifications. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 10527-10543.	6.4	118
4	Synthetic Approaches to the New Drugs Approved During 2015. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 6480-6515.	6.4	103
5	Synthetic approaches to the 2014 new drugs. <i>Bioorganic and Medicinal Chemistry</i> , 2016, 24, 1937-1980.	3.0	84
6	Synthetic approaches to the 2011 new drugs. <i>Bioorganic and Medicinal Chemistry</i> , 2013, 21, 2795-2825.	3.0	80
7	RN927C, a Site-Specific Trop-2 Antibody-Drug Conjugate (ADC) with Enhanced Stability, Is Highly Efficacious in Preclinical Solid Tumor Models. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 2698-2708.	4.1	78
8	Synthetic approaches to the 2009 new drugs. <i>Bioorganic and Medicinal Chemistry</i> , 2011, 19, 1136-1154.	3.0	76
9	Discovery of 4-(5-Methyloxazol[4,5- <i>b</i> ]pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane (CP-810,123), a Novel $\alpha 7$ Nicotinic Acetylcholine Receptor Agonist for the Treatment of Cognitive Disorders in Schizophrenia: Synthesis, SAR Development, and in Vivo Efficacy in Cognition Models. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 1222-1237.	6.4	68
10	Synthetic approaches to the 2013 new drugs. <i>Bioorganic and Medicinal Chemistry</i> , 2015, 23, 1895-1922.	3.0	63
11	Synthetic approaches to the 2010 new drugs. <i>Bioorganic and Medicinal Chemistry</i> , 2012, 20, 1155-1174.	3.0	59
12	Synthetic Approaches to New Drugs Approved During 2016. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 7004-7031.	6.4	58
13	Spliceostatin hemiketal biosynthesis in <i>Burkholderia</i> spp. is catalyzed by an iron/ $\alpha$ -ketoglutarate-dependent dioxygenase. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, E3376-85.	7.1	55
14	Site Selection: a Case Study in the Identification of Optimal Cysteine Engineered Antibody Drug Conjugates. <i>AAPS Journal</i> , 2017, 19, 1123-1135.	4.4	51
15	Development of Solid-Phase Site-Specific Conjugation and Its Application toward Generation of Dual Labeled Antibody and Fab Drug Conjugates. <i>Bioconjugate Chemistry</i> , 2016, 27, 1030-1039.	3.6	50
16	Synthetic Approaches to the New Drugs Approved During 2017. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 7340-7382.	6.4	44
17	Synthetic approaches to the 2012 new drugs. <i>Bioorganic and Medicinal Chemistry</i> , 2014, 22, 2005-2032.	3.0	40
18	Synthetic Approaches to New Drugs Approved during 2018. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 10652-10704.	6.4	33

#	ARTICLE	IF	CITATIONS
19	PF-06804103, A Site-specific Anti-HER2 Antibody-Drug Conjugate for the Treatment of HER2-expressing Breast, Gastric, and Lung Cancers. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 2068-2078.	4.1	32
20	Novel Anti-TM4SF1 Antibody-Drug Conjugates with Activity against Tumor Cells and Tumor Vasculature. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 1868-1876.	4.1	31
21	Synthetic Approaches to the New Drugs Approved during 2019. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 3604-3657.	6.4	30
22	Multivalent peptidic linker enables identification of preferred sites of conjugation for a potent thalianstatin antibody drug conjugate. <i>PLoS ONE</i> , 2017, 12, e0178452.	2.5	24
23	Synthetic Approaches to the 2008 New Drugs. <i>Mini-Reviews in Medicinal Chemistry</i> , 2009, 9, 1655-1675.	2.4	23
24	The Discovery and Characterization of the $\hat{\pm}$ -Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid (AMPA) Receptor Potentiator $\langle i \rangle N \langle /i \rangle - \{ (3 \langle i \rangle S \langle /i \rangle , 4 \langle i \rangle S \langle /i \rangle ) - 4 - [ 4 - ( 5 - \text{Cyano-2-thienyl} ) \text{phenoxy} ] \text{tetrahydrofuran-3-yl} \} \text{propane-2-sulfonamide}$ (PF-04958242). <i>Journal of Medicinal Chemistry</i> , 2015, 58, 4291-4308.	6.4	23
25	Identification of a Potent, Highly Selective, and Brain Penetrant Phosphodiesterase 2A Inhibitor Clinical Candidate. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 1001-1018.	6.4	23
26	Synthetic Approaches to the 2007 New Drugs. <i>Mini-Reviews in Medicinal Chemistry</i> , 2008, 8, 1526-1548.	2.4	21
27	Synthetic Approaches to the New Drugs Approved During 2020. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 9607-9661.	6.4	18
28	Synthesis and SAR studies of 1,4-diazabicyclo[3.2.2]nonane phenyl carbamates $\hat{\pm}$ subtype selective, high affinity $\hat{\pm} 7$ nicotinic acetylcholine receptor agonists. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 4747-4751.	2.2	14
29	Development of Highly Optimized Antibody-Drug Conjugates against CD33 and CD123 for Acute Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2021, 27, 622-631.	7.0	11
30	NOTCH3-targeted antibody drug conjugates regress tumors by inducing apoptosis in receptor cells and through transendocytosis into ligand cells. <i>Cell Reports Medicine</i> , 2021, 2, 100279.	6.5	7
31	Novel PIKK inhibitor antibody-drug conjugates: Synthesis and anti-tumor activity. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2019, 29, 943-947.	2.2	6
32	CXI Dimers as Antibody-Drug Conjugate (ADC) Payloads. <i>RSC Drug Discovery Series</i> , 2019, , 209-240.	0.3	2